Skip to main content
Premium Trial:

Request an Annual Quote

Bristol Myers Squibb, Medic Life Sciences Collaborate on Tumor Target Discovery

NEW YORK – Medic Life Sciences said on Monday that it has entered into a research collaboration with Bristol Myers Squibb on target discovery for solid tumors.

Under the terms of the deal, Medic will use its 3D tumor models to perform CRISPR-based functional genomic screens in solid tumor indications. The startup will also use its immune cell and tumor cell co-culture platform to identify novel genes relevant to immune cell-based elimination of cancer cells. Medic will receive upfront payments and will be eligible for additional option payments on a target-by-target basis, as well as future development and regulatory milestone payments.

Other terms of the deal were not disclosed.

Founded in 2020, Medic is a graduate of the Illumina Accelerator program. In a statement, the firm added that it has received an undisclosed amount of funding from TOP Harvest Capital, Primer Sazze Partners, Big Basin Capital, and First In Ventures.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.